×

Do you want to link to this External Site and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen Site outside the UK and leave Amgen.co.uk?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Please note, this page is intended for UK healthcare professionals. By clicking to enter this page you are confirming that you are a UK healthcare professional.

×

Do you want to link to this Amgen Site and leave Amgen.co.uk?

Please note this site is only intended for UK Healthcare professionals and UK patients that have been prescribed Prolia®

YOU ARE NOW LEAVING THIS WEBSITE.

New Review Of The State Of The Nation In Multiple Myeloma Published

Expert contributors from the fields of medicine, nursing and patient advocacy call for action in earlier diagnosis, treatment research and equity of access to current care services and treatment in the UK

Cambridge, UK, 19 April, 2016: Published today, a new report – “State of the nation in multiple myeloma – a UK perspective” – sets out the discussions and consensus of a group of experts as they consider the current challenges and visions for the future in multiple myeloma. Clinical, economic, public health and patient perspectives are reviewed in a comprehensive publication which recognises progress over the past 40 years and offers a ‘call to action’ to all stakeholders in the myeloma field.

In its Visions for myeloma 2025 this State of the Nation report outlines three key areas:

  1. Earlier diagnosis of myeloma supported by increased education, better testing and research in early-stage disease
  2. Improved treatment options and further research focused on the underlying biology of the disease, control of symptoms and management of disease progression
  3. Equity of access to care and treatment across regions, patient ages, gender and race – linked to better interaction with health technology assessment bodies and further improvement in clinical research

The report seeks to drive further discussion with the aim of continued improvements and collaborations in patient care over the coming decade, and beyond.

To access the full report, click on the image below:

Notes For Editors

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

For more information, visit www.amgen.co.uk.

About The Report

“State of the nation in multiple myeloma – a UK perspective” was supported by an educational grant from Amgen.

Written by an independent medical writer, the report is based on the discussions and consensus of a multidisciplinary expert group which met in London on 19 January 2016.

About Multiple Myeloma

Although multiple myeloma is not as widely known as other types of cancer, it is the second most common haematological cancer in the UK,1 characterised by unregulated plasma cell proliferation. With approximately 4,900 new cases diagnosed each year,2 the UK incidence rate is ninth highest in Europe for males and eighth highest for females.2 It is estimated that around 15,000-20,000 people are living with myeloma in the UK.3 Multiple myeloma is an aggressive cancer with less than half of patients surviving for five years,4 leading to more than 2,700 deaths in the UK in 2012.5

CONTACT:    James Read, Amgen, UK & Ireland

Phone: +44 (0) 7585 404909

Email: james.read@amgen.com

References

  1. Cancer Research UK. Cancer incidence for common cancers. Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Zero [accessed 14 April 2016]
  2. Cancer Research UK. Myeloma statistics. Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma#heading-Zero [accessed 14 April 2016]
  3. Myeloma UK – Myeloma: Essential Guide. Available at: http://www.myeloma.org.uk/wp-content/uploads/2013/09/Myeloma-UK-Living-well-with-myeloma-Essential-Guide-Nov-2015.pdf [accessed 14 April 2016]
  4. NIH SEER Programme. SEER Stat Fact Sheets: Myeloma. Available at http://seer.cancer.gov/statfacts/html/mulmy.html [accessed 14 April 2016]
  5. Cancer Research UK. Myeloma mortality statistics. Available at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/mortality#heading-Zero [accessed 14 April 2016]
Date of preparation: April 2016

UKIE-CC-NPS-0216-124622b